The article highlights the challenges in addressing the obesity pandemic, noting that traditional advice to exercise more and eat less has limited effectiveness for most individuals. A 2023 Science article emphasizes the lack of consensus on obesity's causes, disputing the assertion that sedentary behavior is the primary culprit. The article details how semaglutide, a diabetes drug, has emerged as an effective treatment, leading to significant weight loss. Its competitor, tirzepatide, demonstrates even higher weight loss results, with the pharmaceutical industry rapidly expanding into this lucrative market, potentially reaching $100 billion by 2030.
Despite decades of simplistic advice to "move more and eat less," over 80% of those struggling with obesity find it only works in the short term.
The FDA's approval of semaglutide has changed the landscape of obesity treatment, allowing people to experience weight loss of up to 15% in 68 weeks.
There is ongoing uncertainty about the causes of obesity, with claims linking sedentary behavior to the obesity epidemic lacking substantial evidence.
Pharmaceutical companies are heavily investing in obesity treatments, with projections suggesting the market could reach $100 billion by 2030.
Collection
[
|
...
]